$IBEX

Dechant Robert Thomas sold $225K of IBEX

Dechant Robert Thomas (Chief Executive Officer) sold 5,000 shares of IBEX Ltd (IBEX) at $45.02 ($0.23M total) on 2026-09-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Dechant Robert Thomas
Published Sep 29, 2026, 9:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 9:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IBEX
Bearish
medium confidence
Mentioned
$IBEX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IBEXBearishLow
01

Why it matters

A modest insider sell by the CEO may cause short‑term price pressure but is unlikely to drive major moves.

02

Market read

Limited; primarily of interest to short‑term traders watching insider activity.

03

What to watch

CEO still retains a large stake (257,011 shares) indicating confidence.

Relevance 3/10Novelty 3/10Timing: post-market today

Background

Form 4 filings disclose insider transactions; traders monitor them for potential signals.

Company-level read

Ticker impact

$IBEXBearishMedium confidence
Context

CEO Robert Thomas sold 5,000 shares for $225K via a Form 4 filing.

Expected impact

likely modest pressure as the market prices in the insider sell

Evidence & confidence

The sale is modest in size relative to holdings, but any insider sell can prompt short-term downside bias.

Market effects

None significant; the sale is company‑specific.

Minimal impact on broader market.

Low

Counterpoint

The sale could be routine liquidity need, not a negative signal.

Key entities

  • IBEX Ltd

    Issuer of the Form 4 filing.

  • Robert Thomas

    CEO and director of IBEX Ltd.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IBEXHighAI 8/10

IBEX (IBEX) Turns The AI Threat Into Its Biggest Growth Engine

IBEX (IBEX) reported record full-year revenue of $644.1M, up 15.4%, and Q4 revenue of $164.3M, up 11.6%. Growth was driven by HealthTech, Technology, and Travel & Logistics. AI partnerships with Philippine Airlines and BJ's Wholesale showed strong results. Q4 net income fell to $8.7M, and EPS dropped to $0.59 due to training and operational costs.

$IBEXMedAI 8/10

IBEX (IBEX) Q4 2026 Earnings Call Transcript

IBEX (IBEX) reported fiscal year 2026 revenue of $644.1 million, up 15.4%, with Q4 revenue at $164.3 million, up 11.6%. Adjusted EBITDA reached $82.4 million, a 14.5% increase. HealthTech revenue grew 38.5% to $114 million. Guidance for 2027 projects revenue of $700M-$715M and adjusted EBITDA of $90M-$94M. The company highlighted growth in AI-powered services and strategic partnerships.

$IBEXHigh

IBEX Reports Record Fiscal Year 2026 Financial Results, Introduces Fiscal Year 2027 Guidance

IBEX Ltd (IBEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IBEX Reports Record Fiscal Year 2026 Financial Results, Introduces Fiscal Year 2027 Guidance • Record fourth quarter revenue grew 12% versus prior year quarter, sixth consecutive quarter of double-digit growth • Nine new logo wins in the fourth quarter, including two